ExpreS2ion Biotech Holding AB
The answer first
Does ExpreS2ion Biotech Holding beat the market?
No, ExpreS2ion Biotech Holding has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 25% of Nordic stocks
- Quality53
- Value58
- Trend5
No. 117 of 195 in healthcare
Max for seven days
Follow ExpreS2ion Biotech Holding with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about ExpreS2ion Biotech Holding
Your first answer is free, no account needed.
Do you own ExpreS2ion Biotech Holding, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with ExpreS2ion Biotech Holding and a few more. Free, no card.
Super Stock+45.9%In short
- ExpreS2ion Biotech Holding has fallen 85.0% over the past year, including dividends.
- Overall, ExpreS2ion Biotech Holding ranks better than 25% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 98.8%. The price is 99.9% below its peak now.
What do analysts think of ExpreS2ion Biotech Holding?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 25% of Nordic stocks.
No. 117 of 195 in healthcare
Medium An average company: the accounts are neither especially strong nor weak.
No. 121 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.07
- Asset turnoverSales divided by everything the company owns0.10
- Return on equityProfit divided by equity−114.5%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
Medium Fair price: about the same as a typical Nordic stock.
No. 32 of 197 in healthcareTypical in healthcare: 21Typical in the Nordics: 50
- P/BPrice divided by equity0.7
- P/SPrice divided by sales4.6
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flownegative earnings
The ranking is built on P/E, P/B and P/S.
Low Headwind in the share price: it has done worse than most over the last year.
No. 174 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−27.9%
- 6 months−44.9%
- 9 months−82.6%
- 12 months−85.0%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
About ExpreS2ion Biotech Holding
ExpreS2ion Biotech Holding AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 19 employees.
ExpreS2ion Biotech Holding AB (publ), a clinical-stage biotechnology company, develops protein-based immunotherapies and vaccines for oncology and infectious diseases in the Nordics and internationally. The company's lead asset is ES2B-C001, an immunotherapy candidate, which is in Phase 1 clinical trials for breast cancer that targets the human epidermal growth factor receptor 2, as well as vaccines for Nipah virus, Malaria, and influenza. It also offers GlycoX-S2, a glyco-engineered variants of the ExpreS2 platform to modify glycosylation patterns in expressed proteins. The company has collaboration agreement with University of Oxford for the development of vaccine for malaria.


See the full analysis of ExpreS2ion Biotech Holding.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card